Application of proteomics to the study of polycystic ovary syndrome
Tóm tắt
Background: Clinical proteomics consists of qualitative and quantitative profiling of proteins present in clinical specimens such as body fluids or tissues, with the aim of discovering novel proteins and cellular pathways associated with the disease of interest. Aim: To review the proteomic studies conducted to date that addressed different aspects of the pathogenesis of polycystic ovary syndrome (PCOS). Methods: Descriptive review of studies that applied proteomic techniques to the study of PCOS. Published articles were identified using the Entrez-PubMed online search facilities. Results: Most studies conducted to date focused on protein variations in plasma and different target tissues. Plasma proteomics analysis revealed that PCOS associates changes in protein expression in several acute-phase response proteins. Moreover, some of these molecules play major roles in iron metabolism and low-grade chronic inflammation. Studies using omental adipose tissue from morbidly obese women with or without PCOS revealed differences in abundance of proteins that may be involved in lipid and glucose metabolism, oxidative stress processes, and adipocyte differentiation. Moreover, identification of differentially expressed proteins in ovarian tissue, granulosa cells or T lymphocites may help to characterize more clearly some aspects of this disorder. Conclusions: Although the application of proteomic techniques to the study of PCOS is in its early infancy, studies conducted to date highlight its heterogeneous nature. Aside from androgen excess, several pathways related to intermediate metabolism, oxidative stress processes, inflammation and iron metabolism appear to be involved in the pathophysiology of PCOS.
Tài liệu tham khảo
Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999, 84: 1897–9.
Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000, 85: 2434–8.
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89: 2745–49.
Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol Obstet Invest 2010, 69: 274–80.
Azziz R, Carmina E, Dewailly D, et al; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006, 91: 4237–45.
Garcia-Romero G, Escobar-Morreale HF. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus. Curr Diabetes Rev 2006, 2: 39–49.
Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006, 166: 2081–6.
Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010, 95: 2038–49.
Wickenheisser JK, Nelson-DeGrave VL, McAllister JM. Human ovarian theca cells in culture. Trends Endocrinol Metab 2006, 17: 65–71.
DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005, 83: 1454–60.
Nahum R, Thong KJ, Hillier SG. Metabolic regulation of androgen production by human thecal cells in vitro. Hum Reprod 1995, 10: 75–81.
Tosi F, Negri C, Brun E, et al. Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women. Eur J Endocrinol 2011, 164: 197–203.
Escobar-Morreale HF, San Millán JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007, 18: 266–72.
Goumenou AG, Matalliotakis IM, Koumantakis GE, Panidis DK. The role of leptin in fertility. Eur J Obstet Gynecol Reprod Biol 2003, 106: 118–24.
Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002, 26: 883–96.
Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 2006, 21: 2257–65.
Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 2011, 95: 1048–58. e1–2.
San Millán JL, Alvarez-Blasco F, Luque-Ramírez M, Botella-Carretero JI, Escobar-Morreale HF. The PON1-108C/T polymorphism, and not the polycystic ovary syndrome, is an important determinant of reduced serum paraoxonase activity in premenopausal women. Hum Reprod 2006, 21: 3157–61.
Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005, 26: 251–82.
Escobar-Morreale HF, Insenser M, Cortón M, Millán JL, Peral B. Proteomics and genomics: A hypothesis-free approach to the study of the role of visceral adiposity in the pathogenesis of the polycystic ovary syndrome. Proteomics Clin Appl 2008, 2: 444–55.
Ly L, Wasinger VC. Protein and peptide fractionation, enrichment and depletion: Tools for the complex proteome. Proteomics 2011, 11: 513–34.
Weiss W, Görg A. High-resolution two-dimensional electrophoresis. Methods Mol Biol 2009, 564: 13–32.
Gloerich J, Wevers RA, Smeitink JA, van Engelen BG, van den Heuvel LP. Proteomics Approaches to Study Genetic and Metabolic Disorders. J Proteome Res 2006, 6: 506–12.
Scott EM, Carter AM, Findlay JB. The application of proteomics to diabetes. Diab Vasc Dis Res 2005, 2: 54–60.
Süss C, Solimena M. Proteomic profiling of beta-cells using a classical approach — two-dimensional gel electrophoresis. Exp Clin Endocrinol Diabetes 2008, 116: S13–20.
Wong SC, Chan CM, Ma BB, et al. Advanced proteomic technologies for cancer biomarker discovery. Expert Rev Proteomics 2009, 6: 123–34.
Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18: 2071–7.
Minden JS, Dowd SR, Meyer HE, Stuhler K. Difference gel electrophoresis. Electrophoresis 2009, 30 (Suppl): S156–61.
Lescuyer P, Hochstrasser DF, Sanchez J-C. Comprehensive proteome analysis by chromatographic protein prefractionation. Electrophoresis 2004, 25: 1125–35.
Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003, 422: 198–207.
Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 1993, 7: 576–80.
Chapman K. The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans 2002, 30: 82–7.
Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics 2006, 6: 6326–53.
Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1: 845–67.
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19: 41–47.
Matharoo-Ball B, Hughes C, Lancashire L, et al. Characterization of biomarkers in polycystic ovary syndrome (PCOS) using multiple distinct proteomic platforms. J Proteome Res 2007, 6: 3321–8.
Insenser M, Martinez-Garcia MA, Montes R, San-Millan JL, Escobar-Morreale HF. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation. J Clin Endocrinol Metab 2010, 95: 3863–70.
Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR (eds). Polycystic ovary syndrome. Boston: Blackwell Scientific Publications. 1992, 377–84.
Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millán JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005, 90: 6364–9.
Zhao SY, Qiao J, Li MZ. Protein expression profilings of polycystic ovary syndrome. Beijing Da Xue Xue Bao 2005, 37: 362–5.
Zhao S, Qiao J, Li M, Zhang X, Yu J, Li R. Discovery of distinct protein profiles for polycystic ovary syndrome with and without insulin resistance by surface-enhanced laser adsorption/ionization time of flight mass spectrometry. Fertil Steril 2007, 88: 145–51.
Kershaw EE, Flier JS. Adipose tissue asan endocrine organ. J Clin Endocrinol Metab 2004, 89: 2548–56.
Corton M, Villuendas G, Botella JI, San Millan JL, Escobar-Morreale HF, Peral B. Improved resolution of the human adipose tissue proteome at alkaline and wide range pH by the addition of hydroxyethyl disulfide. Proteomics 2004, 4: 438–41.
Corton M, Botella-Carretero JI, Lopez JA, et al. Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. Hum Reprod 2008, 23: 651–61.
Ma X, Fan L, Meng Y, et al. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Mol Hum Reprod 2007, 13: 527–35.
Choi DH, Lee WS, Won M, et al. The apolipoprotein A-I level is downregulated in the granulosa cells of patients with polycystic ovary syndrome and affects steroidogenesis. J Proteome Res 2010, 9: 4329–36.
Borro M, Gentile G, Stigliano A, Misiti S, Toscano V, Simmaco M. Proteomic analysis of peripheral T lymphocytes, suitable circulating biosensors of strictly related diseases. Clin Exp Immunol 2007, 150: 494–501.
Misiti S, Stigliano A, Borro M, et al. Proteomic profiles in hyperandrogenic syndromes. J Endocrinol Invest 2010, 33: 156–64.